|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Current assets | ||||||||||||
| Cash and cash equivalents | ||||||||||||
| Restricted cash | ||||||||||||
| Short-term deposits | ||||||||||||
| Marketable debt securities | ||||||||||||
| Other receivables | ||||||||||||
| Total current assets | ||||||||||||
| Operating lease right-of-use assets | ||||||||||||
| Property and equipment, net | ||||||||||||
| Investment in associate at fair value | ||||||||||||
| Loan to associate | ||||||||||||
| Total non-current assets | ||||||||||||
| Total assets | ||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||
| Current liabilities | ||||||||||||
| Trade payables | ||||||||||||
| Other payables | ||||||||||||
| Total current liabilities | ||||||||||||
| Stockholders’ equity | ||||||||||||
| Ordinary shares, par value NIS 1.80 per share; Authorized 900,000,000 shares; Issued and outstanding: 6,581,390 and 1,664,884 shares as of December 31, 2025 and December 31, 2024, respectively | ||||||||||||
| Additional paid-in capital | ||||||||||||
| Accumulated other comprehensive loss | ||||||||||||
| Accumulated deficit | ||||||||||||
| Total stockholders’ equity | ||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||
Loading...